Semax
ACTH-Derived Neuroprotective Peptide
Semax is an ACTH(4-10) analogue developed in Russia, where it has been used clinically for stroke recovery, cognitive enhancement, and neuroprotection for decades. In Western research contexts it is primarily studied as a nootropic and neuroprotective compound with a particularly well-characterized BDNF-upregulation mechanism.
At a Glance
Despite being derived from adrenocorticotropic hormone (ACTH), Semax has no meaningful effect on cortisol or steroid pathways. Instead, it was engineered to retain and amplify the neuroprotective fragment of ACTH while eliminating the hormonal cascade — making it a cleaner cognitive research tool than its parent compound.
Its primary mechanism involves upregulation of BDNF (brain-derived neurotrophic factor) — the primary growth factor supporting neuronal survival, plasticity, and new neuron formation. This places Semax at the intersection of neuroprotection, learning, and mood regulation research.
Its nasal spray formulation — used clinically in Russia — has also made it one of the few research peptides with a well-established intranasal administration model, providing data on CNS delivery via olfactory and nasal routes.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
BDNF Upregulation
Stimulates expression of brain-derived neurotrophic factor, supporting neuronal survival, synaptic plasticity, and neurogenesis in preclinical cognitive models.
ACTH Analogue — No Steroid Effect
Derived from ACTH(4-10) but engineered to eliminate steroid pathway activation — retaining neuroprotective effects without hormonal side effects.
Dopamine & Serotonin Modulation
Influences dopaminergic and serotonergic signaling, contributing to studied effects on motivation, focus, and mood regulation.
Neuroprotection
Demonstrated protective effects in ischemic injury models — reducing neuronal death and improving functional recovery in stroke animal models.
Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.
- Stroke recovery and neuroprotection — primary clinical application in Russia; preclinical models widely studied
- Cognitive function and learning — BDNF-mediated neuroplasticity enhancement in rodent models
- Anxiety and stress response — anxiolytic properties in animal studies without sedation
- ADHD and attention research — dopamine modulation and focus studies
- Depression models — BDNF pathway connection to antidepressant mechanisms
- Neuroinflammation research — anti-inflammatory effects in CNS injury models
- Intranasal CNS delivery models — well-established route from clinical use
Semax occupies a unique position as a compound with substantial Eastern European clinical history but limited Western regulatory review — providing an unusually rich human dataset relative to most research peptides.
Semax and Selank are the most commonly compared cognitive peptides from Russian research — they're often studied together due to complementary mechanisms.
| Aspect | Semax | Selank | Cerebrolysin |
|---|---|---|---|
| Primary Mechanism | BDNF upregulation, ACTH analogue | Anxiety reduction, immune modulation | Neurotrophic factor mixture |
| Main Research Use | Cognition, stroke recovery | Anxiety, PTSD, cognition | Neuroprotection, dementia |
| Administration | Intranasal or SC | Intranasal or SC | IV or IM injection |
| Human Clinical Data | Substantial (Russia) | Growing (Russia) | Substantial (Eastern Europe) |
| Stimulating Effect | Mild stimulating | Calming/anxiolytic | Neutral |
The following reflects findings from published preclinical and clinical safety assessments where available.
Human clinical data available — decades of stroke and cognitive research in Russia provides unusual human evidence base
Well-characterized BDNF mechanism — one of the more clearly understood nootropic peptides at the mechanistic level
Intranasal route established — clinical formulation history provides delivery model data
Western regulatory status limited — not FDA approved; most Western researchers rely on translated or limited-access Russian clinical literature
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026